Pfizer to scale down early-stage rare disease research
Pfizer said its oncology research portfolio will become even more focused around breast, prostate and hematological cancer franchises.
Advertisement
New York: U.S. pharma giant Pfizer Inc said on Thursday it is planning to realign its early-stage research into treatments for rare diseases and oncology, to focus on areas like rare and benign haematology.
Pfizer will also move away from having a rare disease research unit to align important rare disease programs to areas across its research units.
"We are refocusing our approach to early discovery and development research in rare disease and oncology," a spokesperson said in a statement to Reuters, adding that the company will explore externalization opportunities for "a number of highly innovative, niche programs."
Pfizer said its oncology research portfolio will become even more focused around breast, prostate and hematological cancer franchises.
Financial newspaper Barron's first reported the news on Thursday.
Read also: Pfizer India announces 12-week paternity leave policy for its workforce
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.